4 active not recruiting, 3 completed, 3 terminated, 1 recruiting. 9 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Active not recruiting 3, Terminated 3, Completed 2, Recruiting 1 |
| Phase 1 | 5 | Completed 3, Active not recruiting 1, Terminated 1 |
Follow HuMax-IL8: new trials by email Literature Review of HuMax-IL8 trials Research Report on HuMax-IL8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BMS-986253 in Myelodysplastic Syndromes Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253 - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2022-11-29 | 2025-09-30 |
| Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma nivolumab, BMS-986253, Stereotactic Body Radiotherapy (SBRT) - Melanoma, Unresectable Solid Tumors | Phase 1 | Active not recruiting | Yana Najjar | 50 | 2021-11-29 | 2026-08-20 |
| Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca Nivolumab, HuMax-IL8 - Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 24 | 2021-04-24 | 2026-05-14 |
| Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19 BMS-986253 - Solid Tumor, Sars-CoV2 | Phase 2 | Terminated | Columbia University | 43 | 2020-04-16 | 2025-05-22 |
| Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) Nivolumab, BMS-813160, BMS-986253 - Non-small Cell Lung Cancer, Hepatocellular Carcinoma | Phase 2 | Active not recruiting | Icahn School of Medicine at Mount Sinai | 48 | 2020-03-05 | 2026-09-25 |
| Nivolumab Combined With BMS-986253 in HCC Patients Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks, Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks, Nivolumab 240 mg IV every 2 weeks - Hepatocellular Carcinoma | Phase 2 | Terminated | NYU Langone Health | 13 | 2019-09-12 | 2025-10-16 |
| Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) Nivolumab, Degarelix, BMS-986253 - Prostate Cancer, Adenocarcinoma of the Prostate | Phase 1 / Phase 2 | Completed | Mark Stein | 59 | 2018-10-11 | 2026-10-15 |
| A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers BMS-986253, Nivolumab, Ipilimumab - Cancer, Melanoma | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 281 | 2018-02-12 | 2026-02-24 |
| Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer Nivolumab, Ipilimumab, Celecoxib 200mg - Colon Carcinoma | Phase 2 | Recruiting | The Netherlands Cancer Institute | 353 | 2017-03-29 | 2026-09-30 |
| Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas Cyclophosphamide, GVAX pancreatic cancer, Nivolumab - Pancreatic Cancer | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 76 | 2016-03-28 | 2026-10-13 |
| HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors HuMax-IL8 - Solid Tumor | Phase 1 | Completed | Bristol-Myers Squibb | 15 | 2015-08-01 | 2017-02-03 |
Carcinoma, Hepatocellular (2) · Melanoma (2) · Neoplasms (2) · COVID-19 (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Coronavirus Infections (1) · Cytopenia (1) · Hematologic Neoplasms (1) · Myelodysplastic Syndromes (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Bristol-Myers Squibb (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Columbia University (1) · Icahn School of Medicine at Mount Sinai (1) · Mark Stein (1) · NYU Langone Health (1) · National Cancer Institute (NCI) (1) · The Netherlands Cancer Institute (1) · Yana Najjar (1)
United States (10) · Australia (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · Sweden (1) · Switzerland (1) · United Kingdom (1)
Ana De Jesus-Acosta, MD (1) · Carole Fakhry, M.D. (1) · Mark N Stein, MD (1) · Mark N. Stein, MD (1) · Myriam Chalabi, MD (1) · Najla El Jurdi, M.D. (1) · Nina Beri, MD (1) · Thomas Marron, MD PhD (1) · Yana Najjar, MD, FACP (1)
PMID 31488216, PMID 32251400, PMID 34606846, PMID 37339979, PMID 38838311, PMID 38838316, PMID 39278994, PMID 40318595, PMID 41115454
2023 (1), R01CA197296 (1)